Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Loncar Investment Starts China Biopharma Stock Index

publication date: Mar 15, 2018

Loncar Investments has launched its Loncar China Biopharma Index (LCHINA), an index comprised of 32 China publicly traded biotech companies. The index, which is re-priced once a day, includes innovative life science companies that are listed in Hong Kong or on NASDAQ. Loncar said it introduced the LCHINA Index because of the growing interest in China biopharma investments, creating the need for a read on the strength of the sector. The Index started operating on February 13, 2018, at a value of 1,000. One month later it is at 1129.71, a 13% increase. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital